Status:
UNKNOWN
M-ROSE Combined With mNGS in Severe Hospital-acquired Pneumonia
Lead Sponsor:
Chinese PLA General Hospital
Collaborating Sponsors:
Beijing Chao Yang Hospital
Beijing Anzhen Hospital
Conditions:
Pneumonia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine the value of M-ROSE（microbiological rapid on-site evaluation）in severe hospital-acquired pneumonia.
Detailed Description
Severe hospital acquired pneumonia (SHAP) is the critical risk factor leading to the death of nosocomial infection patients. Rapid identification of pathogens, guidance of individualized treatment and...
Eligibility Criteria
Inclusion
- Clinical diagnosis of severe hospital-acquired pneumonia
- Must have undergone bronchoalveolar lavage
Exclusion
- BALF samples were not sent for mNGS examination
- Age \< 18 years old
- The hospitalization days ≤ 3
- The clinical data are incomplete
- Mechanical ventilation time \> 60 days
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
166 Patients enrolled
Trial Details
Trial ID
NCT05300776
Start Date
May 1 2022
End Date
December 31 2024
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yi Tao
Beijing, Beijing Municipality, China, 100083